Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
ALK-positive
100%
Anaplastic Lymphoma Kinase-positive
66%
CD20
33%
Lymphoma
33%
HHV-8
33%
Plasmablastic
33%
Immunosuppression
16%
Immunohistochemistry
16%
Clinical Features
16%
Aggressive Behavior
16%
Pathological Features
16%
Nodal Involvement
16%
MEDLINE
16%
Pediatric
16%
Poor Response
16%
CD30
16%
Extensive Literature Search
16%
Nasal Fossa
16%
Behavioral Response
16%
MUM1
16%
Plasmacytic Differentiation
16%
WHO Classification
16%
IPI Score
16%
Comprehensive Comparison
16%
B Symptoms
16%
CD45
16%
Prolonged Survival
16%
Extranodal Disease
16%
Primary Extranodal
16%
Clinicopathological Differences
16%
ALK-positive Large B-cell Lymphoma
16%
Incidence Graph
16%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Anaplastic Lymphoma Kinase
66%
CD20
33%
Epstein Barr Virus
33%
Disease
16%
Prospective Study
16%
Aggression
16%
Pediatrics
16%
Immunohistochemistry
16%
Immunosuppressive Treatment
16%
Lactate Dehydrogenase
16%
Nasal Fossa
16%
Anaplastic Large Cell Lymphoma
16%
B Symptoms
16%
CD3 Antigen
16%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Anaplastic Lymphoma Kinase
80%
CD20
40%
Epstein Barr Virus
40%
Lactate Dehydrogenase
20%
CD30
20%
Aggression
20%
Prospective Study
20%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Anaplastic Lymphoma Kinase
66%
Disease
16%
Lactate Dehydrogenase
16%
Prospective Study
16%
Anaplastic Large Cell Lymphoma
16%
CD3 Antigen
16%